Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. (Huaheng Bio) has submitted an application for listing on the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1]. Company Overview - Huaheng Bio is a pioneer in synthetic biology, focusing on the research, large-scale production, and commercialization of bio-based products through biomanufacturing technology. The company has established a leading position in the industry over the past 20 years [3]. - The company is recognized as one of the most comprehensive enterprises in the commercialization of bio-based products through synthetic biology, being the first globally to industrialize the anaerobic fermentation of a series of amino acids, including L-Alanine and L-Valine. By 2024, it is projected to hold the largest market share for L-Alanine and L-Valine globally [3]. Product Portfolio - As of June 30, 2025, Huaheng Bio has established stable long-term partnerships with over 768 customers across 85 countries in Asia, Europe, and the Americas. Its main bio-based products include amino acids (primarily alanine series, L-Valine, tryptophan, arginine), vitamins (D-Calcium Pantothenate, D-Pantothenol, inositol), and other bio-based products (1,3-propanediol, succinic acid, malic acid, arbutin) [4]. - The company employs two green manufacturing technology platforms: fermentation and enzyme catalysis, focusing on microbial cell factories and enzyme-based production processes to reduce pollution, lower energy consumption, and minimize carbon footprints [4]. Market Potential - The global bio-based products market is expected to grow from $22.8 billion in 2020 to $42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6%. It is projected to further increase to $80.1 billion by 2030 and $109.1 billion by 2035, with CAGRs of 11.3% and 6.4% respectively [5]. - Companies with green manufacturing capabilities, large-scale production technologies, and collaborative advantages in the supply chain are anticipated to experience unprecedented growth opportunities in this market [5]. Financial Performance - The company reported revenues of approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion for the years 2022, 2023, 2024, and the first half of 2025, respectively. The corresponding profits for these periods were approximately RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5][7].

Core Viewpoint - Anhui Huaheng Biotechnology Co., Ltd. has submitted a listing application to the Hong Kong Stock Exchange, with Huatai International as the sole sponsor [1]. Company Overview - Huaheng Biotechnology is a pioneer in synthetic biology, focusing on the research, large-scale production, and commercialization of bio-based products through biomanufacturing technology [3]. - The company has established an industry-leading position in research and development, technology innovation, and mass production capabilities over the past twenty years in the biomanufacturing field [3]. - According to Frost & Sullivan, Huaheng is one of the most comprehensive companies globally in commercializing bio-based products through synthetic biology [3]. Product Portfolio - The company's bio-based products include amino acids (mainly L-alanine and L-valine), vitamins (such as D-calcium pantothenate and D-panthenol), and other bio-based products like 1,3-propanediol and succinic acid [4]. - These products are widely used across various industries, including animal nutrition, personal care, food and beverage, advanced materials, and plant nutrition [4]. - Huaheng employs fermentation and enzyme catalysis as its two main green manufacturing technology platforms, focusing on microbial cell factories and enzyme-based production processes [4]. Market Potential - The global bio-based products market is projected to grow from USD 22.8 billion in 2020 to USD 42.1 billion by 2024, with a compound annual growth rate (CAGR) of 16.6% [5]. - The market is expected to further increase to USD 80.1 billion by 2030 and USD 109.1 billion by 2035, with CAGRs of 11.3% from 2024 to 2030 and 6.4% from 2030 to 2035 [5]. - Companies with green manufacturing capabilities, large-scale production technologies, and collaborative advantages in the supply chain are anticipated to experience unprecedented growth opportunities in this context [5]. Financial Performance - The company's revenue for the years 2022, 2023, 2024, and the first half of 2025 was approximately RMB 1.419 billion, RMB 1.938 billion, RMB 2.178 billion, and RMB 1.489 billion, respectively [5]. - The corresponding profits for the same periods were about RMB 319 million, RMB 447 million, RMB 185 million, and RMB 109 million [5]. - The gross profit margins for these years were 38.7%, 40.4%, 24.8%, and 23.5%, respectively, indicating fluctuations in profitability [7].

每经AI快讯，9月30日，港交所文件显示，安徽华恒生物科技股份有限公司向港交所提交上市申请书， 独家保荐人为华泰国际。 ...

格隆汇9月30日｜据港交所文件，安徽华恒生物科技股份有限公司向港交所提交上市申请书。 ...

会议召开时间：2025年10月15日（星期三）09:00-10:00 会议召开地点：上海证券交易所上证路演中心（网址：http://roadshow.sseinfo.com/）。 登录新浪财经APP 搜索【信披】查看更多考评等级 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司独立董事吴林先生； 公司董事会秘书邓先河先生。 四、投资者参加方式 会议召开方式：上证路演中心网络互动 投资者可于2025年09月30日（星期二）至10月14日（星期二）16:00登录上证路演中心网站首页点击"提 问预征集"栏目或通过公司邮箱ahb@ehuaheng.com进行提问。公司将在说明会上对投资者普遍关注的问 题进行回答。 安徽华恒生物科技股份有限公司（以下简称"公司"）已于2025年8月28日发布公司2025年半年度报告。 为便于广大投资者更全面深入地了解公司2025年半年度经营成果、财务状况，公司计划于2025年10月15 日（星期三）09:00-10:00举行2025年半年度业绩说明会，就投资者关心的问题进行交流。 ...

香港聯合交易所有限公司與證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何意見，並明確表示概不就因本申請版本全部或任何部分內容而產生或因倚賴該等內容而引致的任何 損失承擔任何責任。 Anhui Huaheng Biotechnology Co., Ltd. 安徽華恒生物科技股份有限公司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警 告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」） 的要求而刊發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資料並不完整，亦可能會作出重大變動。您閱覽本文件，即代 表您知悉、接納並向本公司、其保薦人、整體協調人、顧問或包銷團成員表示同意： 倘於適當時候向香港公眾人士提出要約或邀請，潛在投資者務請僅依據呈交香港公司註冊處註 冊的本公司招股章程作出投資決定；有關文本將於發售期內向公眾刊發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的；投資者不應根據 本文件中的資料作出任何投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或 ...

证券代码：688639 证券简称：华恒生物 公告编号：2025-045 安徽华恒生物科技股份有限公司 二、说明会召开的时间、地点 （一）会议召开时间：2025 年 10 月 15 日（星期三）09:00-10:00 关于召开 2025 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 投资者可于 2025 年 09 月 30 日（星期二）至 10 月 14 日（星期二）16:00 登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 ahb@ehuaheng.com 进行提问。公司将在说明会上对投资者普遍关注的问题进 行回答。 安徽华恒生物科技股份有限公司（以下简称"公司"）已于 2025 年 8 月 28 日发布公司 2025 年半年度报告。为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、财务状况，公司计划于 2025 年 10 月 15 日（星期三） 09:00-10:00 举行 2025 年半年度业绩说明会，就投资者关心的问题进行交流。 一、说明会类型 ...

Investment Rating - Industry investment rating: Overweight [1] Core Views - The chemical sector's overall performance ranked 17th this week, with a decline of 0.95%, underperforming the Shanghai Composite Index by 1.16 percentage points and the ChiNext Index by 2.91 percentage points [4][22] - The chemical industry is expected to continue its trend of differentiated growth in 2025, with recommendations to focus on synthetic biology, pesticides, chromatography media, sweeteners, vitamins, light hydrocarbon chemicals, COC polymers, and MDI [4] Summary by Sections Industry Performance - The chemical sector's performance this week was -0.95%, ranking it 17th among all sectors, while the top three performing sectors were power equipment, non-ferrous metals, and electronics [22][23] - The top three individual stocks in the chemical sector this week were Bluefeng Biochemical (61.16%), Shangwei New Materials (44.81%), and Huarsoft Technology (31.83%) [28] Key Industry Dynamics - A new plan for stable growth in the petrochemical industry was released by seven departments, aiming for an average annual growth of over 5% in value added from 2025 to 2026 [34] - The plan emphasizes the importance of technological innovation, digital empowerment, and environmental sustainability in the petrochemical sector [34] Investment Opportunities - Synthetic biology is highlighted as a key area for growth, with companies like Kasei Biotech and Huaheng Biological being recommended for investment [4][8] - The third-generation refrigerants are expected to enter a high prosperity cycle due to upcoming quota policies and stable demand growth from the air conditioning and cold chain markets [5] - The electronic specialty gases market presents significant domestic substitution opportunities, driven by rapid upgrades in the semiconductor and photovoltaic industries [6][8] - Light hydrocarbon chemicals are identified as a global trend, with a shift towards lighter raw materials expected to enhance the value of leading companies in this sector [8] - The COC polymer industry is accelerating its domestic industrialization process, with companies like AkzoNobel being recommended for attention [9] - Potash fertilizer prices are anticipated to rebound as supply tightens and demand increases due to rising agricultural planting intentions [10] - The MDI market is expected to improve due to oligopolistic supply dynamics and stable demand from polyurethane applications [12]

Investment Rating - The report maintains a "Positive" rating for the chemical industry [5][6][20] Core Insights - The petrochemical industry is expected to see stable growth due to the introduction of policies aimed at enhancing industry health and eliminating outdated capacity [5][6] - The demand for viscose filament is anticipated to tighten, leading to an upward trend in prices, while the grass herbicide market is expected to optimize its structure [5][6] - The global GDP growth is projected to remain at 2.8%, with stable oil demand despite some slowdown due to tariff policies [5][6] Industry Dynamics - Oil supply is expected to increase significantly, driven by non-OPEC production, while demand remains stable [5][6] - The coal market is anticipated to experience long-term price stabilization, with easing pressures on downstream sectors [5][6] - Natural gas exports from the U.S. are likely to accelerate, potentially lowering import costs [5][6] Chemical Sector Analysis - The report highlights that the viscose filament industry will see a supply-demand tightening, with a projected increase in operating rates from 84% to over 95% [5][6] - The grass herbicide market is set to address issues of low pricing and quality through upcoming industry meetings aimed at regulating competition [5][6] Investment Recommendations - The report suggests focusing on sectors benefiting from the "anti-involution" policy, including textiles, agriculture, and export-related chemicals [5][6] - Specific companies to watch include Xinxiang Chemical Fiber, Jilin Chemical Fiber, and Lier Chemical, which are expected to benefit from market dynamics [5][6][20] Key Company Valuations - The report provides a valuation table for key companies, indicating various ratings such as "Buy" and "Increase" for companies like Hailir Chemical, Yunnan Chemical, and Wanhu Chemical [20]

Group 1 - Core viewpoint: Huaheng Biological Technology Co., Ltd. has shown a significant stock price increase of 5.17%, reaching 34.60 CNY per share, with a total market capitalization of 8.654 billion CNY [1] - Company overview: Established on April 13, 2005, and listed on April 22, 2021, the company specializes in the research, production, and sales of amino acids and their derivatives [1] - Revenue composition: The main business revenue is derived from amino acid series (70.96%), followed by other products (20.96%), vitamin series (5.34%), and miscellaneous products (2.74%) [1] Group 2 - Fund holdings: Xinyin Fund has a significant position in Huaheng Biological, with its Xinyin Research Selected Stock A fund holding 41,100 shares, accounting for 2.42% of the fund's net value [2] - Fund performance: The Xinyin Research Selected Stock A fund has achieved a year-to-date return of 24.07% and a one-year return of 54.23%, ranking 2354 out of 4220 and 1673 out of 3824 in its category, respectively [2] - Fund manager: The fund is managed by Qiao Huaguo, who has been in the position for 1 year and 323 days, with the best and worst fund returns during his tenure being 60.78% and 22.15%, respectively [3]